Genetic polymorphism of CYP2C19 and subcortical variability in the human adult brain.
Journal
Translational psychiatry
ISSN: 2158-3188
Titre abrégé: Transl Psychiatry
Pays: United States
ID NLM: 101562664
Informations de publication
Date de publication:
08 09 2021
08 09 2021
Historique:
received:
28
06
2021
accepted:
26
08
2021
revised:
17
08
2021
entrez:
9
9
2021
pubmed:
10
9
2021
medline:
12
10
2021
Statut:
epublish
Résumé
Pharmacogenetic studies have shown involvement of cytochrome P450 enzymes in the metabolism of psychotropic drugs. However, expression and activity on endogenous substrates in the brain may underlie a constitutive role of these enzymes beyond drug metabolism. CYP2C19, which is expressed in the human fetal brain during neurodevelopment, shows affinity for endogenous compounds including monoaminergic neurotransmitters, steroid hormones, and endocannabinoids. In this study (N = 608), we looked at the genetic polymorphism of CYP2C19 and its potential associations with structural phenotypes of subcortical brain volume with structural imaging. Using two independent volume estimation techniques, we found converging evidence for a positive association between CYP2C19 activity scores, as inferred from the genotype, and basal ganglia and hippocampal volume. This association was present only in female individuals, raising the possibility that effects on brain morphology may arise through a mechanism involving the metabolism of estrogen steroids.
Identifiants
pubmed: 34497262
doi: 10.1038/s41398-021-01591-5
pii: 10.1038/s41398-021-01591-5
pmc: PMC8426391
doi:
Substances chimiques
CYP2C19 protein, human
EC 1.14.14.1
Cytochrome P-450 CYP2C19
EC 1.14.14.1
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
467Informations de copyright
© 2021. The Author(s).
Références
Clin Pharmacol Ther. 2006 Jan;79(1):103-13
pubmed: 16413245
Proc Natl Acad Sci U S A. 2005 Dec 27;102(52):19115-20
pubmed: 16357196
Science. 2007 May 25;316(5828):1212-6
pubmed: 17525344
Mol Pharmacol. 2010 Nov;78(5):886-94
pubmed: 20675569
Clin Exp Pharmacol Physiol. 2013 Oct;40(10):683-8
pubmed: 23844835
Mol Psychiatry. 2014 Jun;19(6):733-41
pubmed: 23877834
Brain Cogn. 2010 Feb;72(1):46-55
pubmed: 19913969
Acta Pharmacol Sin. 2001 Feb;22(2):148-54
pubmed: 11741520
Cancer Epidemiol Biomarkers Prev. 2006 Mar;15(3):551-8
pubmed: 16537715
J Clin Oncol. 2007 Nov 20;25(33):5187-93
pubmed: 18024866
J Neurosci. 1999 May 15;19(10):4065-72
pubmed: 10234034
Cereb Cortex. 2001 Jun;11(6):490-7
pubmed: 11375910
Hum Brain Mapp. 1998;6(5-6):348-57
pubmed: 9788071
Neuroimage. 2007 Oct 15;38(1):95-113
pubmed: 17761438
Neuroimage. 2007 Mar;35(1):121-30
pubmed: 17222566
Pharmacogenomics. 2014;15(15):1841-4
pubmed: 25495406
Biol Psychiatry. 2006 May 15;59(10):966-74
pubmed: 16616726
Biol Psychiatry. 2011 Aug 15;70(4):308-9
pubmed: 21791257
Breast Cancer Res Treat. 2009 May;115(2):391-6
pubmed: 18521743
Biol Psychiatry. 2002 Oct 1;52(7):759-63
pubmed: 12372667
J Cereb Blood Flow Metab. 1996 Jan;16(1):7-22
pubmed: 8530558
Hum Brain Mapp. 2012 May;33(5):1246-52
pubmed: 21523857
Neuroimage. 2017 May 15;152:130-141
pubmed: 28254513
Neuroimage. 2011 Jun 1;56(3):907-22
pubmed: 21352927
Physiol Rev. 2008 Jan;88(1):91-124
pubmed: 18195084
Mol Psychiatry. 2013 Mar;18(3):273-87
pubmed: 22565785
Am J Psychiatry. 1998 Jun;155(6):768-73
pubmed: 9619148
Mol Psychiatry. 2017 Aug;22(8):1155-1163
pubmed: 27895323
Life Sci. 2011 Aug 1;89(5-6):165-70
pubmed: 21704641
Neuroimage. 1999 Aug;10(2):107-13
pubmed: 10417245